Treatment also resolved many clinical and lab complications of ADA deficiency such as depleted lymphocyte subset counts, low ADA activity, hypogammaglobulinemia, infections, weight loss etc. Patients that had transitioned from pegademase to elapegademase had no new adverse effects. This evidence concerns the gene ADA and infection.